and as the control peptide:

6. SENKELKKAIDGLQGLLLGLRQRIETLEGK (SEQ ID NO:6)--

Please replace the paragraph beginning at page 6, line 25, with the following:

--Twelve female patients with relatively severe cervical intra-epithelial formations of
neoplasms (ZIN III), 4 of them with a regression indication at the time of the examination
(spontaneous regression of Pap III D to Pap II) Seven female patients with cervix
carcinomas.--

On pages 14-17 of the specification as filed, please delete the Sequence Listing originally filed.

After page 9, please insert the sequence listing for the subject invention, attached hereto, and renumber the specification accordingly.

REMARKS

Entry of the foregoing under 37 C.F.R. § 1.312 is respectfully requested. By the present amendment, the specification has been amended to correct a typographical error. On page 6, line 26, "ZIN" should be --CIN--. CIN means cervical intraepithelial neoplasia.

The specification has also been amended to replace the sequence listing originally filed with a new sequence listing (which is identical to the original, with the exception that it has been updated to be in proper current U.S. Patent and Trademark Office format) and to provide the SEQ ID NO's next to the specific sequence in the specification.

Application No. <u>09/486,394</u> Attorney's Docket No. 032929-001

Page 3

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

In accordance with 37 C.F.R. § 1.312, the appropriate petition fee set forth in 37 C.F.R. § 1.17(i) is enclosed.

In the event that there are any questions relating to this application, it would be appreciated if the Examiner would telephone the undersigned concerning such questions.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Dawn M. Gardner

Registration No. 44,118

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: September 5, 2001

Attachment to Amendment Under 37 C.F.R. § 1.312 dated August 28, 2001

Marked-up Copy

Page 5, Paragraph Beginning at Line 17

- -- The sequences stated in a single letter code for the individual peptides tested were:
- 1. MHGDTPTLHEYMLDLQPETTDLYCYEQLND (SEQ ID NO:1)
- 2. DLYCYEQLNDSSEEEDEIDGPAGQAEPDRA (SEQ ID NO:2)
- 3. PAGQAEPDRAHYNIVTFCCKCDSTLRLCVQ (SEQ ID NO:3)
- 4. CDSTLRLCVQSTHVDIRTLEDLLMGTLGIV (SEQ ID NO:4)
- 5. STHVDIRTLEDLLMGTLGIVCPICSQKP (SEQ ID NO:5) and as the control peptide:
- 6. SENKELKKAIDGLQGLLLGLRQRIETLEGK (SEQ ID NO:6)--

Page 6, Paragraph Beginning at Line 25

--Twelve female patients with relatively severe cervical intra-epithelial formations of neoplasms ([ZIN] <u>CIN</u> III), 4 of them with a regression indication at the time of the examination (spontaneous regression of Pap III D to Pap II) Seven female patients with cervix carcinomas.--